Sign in
Taking peoplePhase 4

Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

Key facts

Who runs it
Melbourne Health
Where
Australia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
100 people, planned
Started
1 Aug 2019
Planned end
30 Dec 2025
Type of study
Interventional
Treatments tested
  • Posaconazole pharmacokinetics
Record updated
28 February 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care
  • Able to give informed consent

Who cannot take part

  • Unable to give informed consent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.

The group in the trial

  • Posaconazole prophylaxisTreatment being tested

    Blood samples will be taken from participants undergoing cancer treatment and receiving Posaconazole prophylaxis. The samples will be used for Posaconazole pharmacokinetics study.

    Treatment: Posaconazole pharmacokinetics

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection
Record updated
28 February 2025